Cancer Antibody Drug Conjugates Treatment Market USD 50 Billion Opportunity Says Kuick Research. Delhi, July 11, 2025 (GLOBE ...

The FDA has set aside reservations it had about the use of Roche’s Polivy as a first-line treatment with chemotherapy for diffuse large B-cell lymphoma (DLBCL), and cleared the new indication ...

Cancer Antibody Drug Conjugates Treatment Market USD 50 Billion Opportunity Says Kuick ResearchDelhi, July 11, 2025 (GLOBE NEWSWIRE) -- Global Cancer Antibody Drug Conjugates Market Size, Drugs ...

Enter Mosun-Pola, which combines mosunetuzumab (Lunsumio), which is FDA-approved for patients with R/R follicular lymphoma after two or more lines of therapy, and polatuzumab vedotin (Polivy ...

Roche’s Polivy (polatuzumab vedotin) was backed by the panel for use in combination with its MabThera (rituximab) antibody and bendamustine chemotherapy in people with previously-treated diffuse ...

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

View today's Chugai Pharmaceutical Co., Ltd. stock price and latest 4519 news and analysis. Create real-time notifications to follow any changes in the live stock price.

See the latest Roche Holding AG stock price (ROG:XSWX), related news, valuation, dividends and more to help you make your investing decisions.